Jiangsu Recbio Technology Co., Ltd. (Recbio) expects a markedly reduced loss for the six months ended 30 June 2026, despite a sharp drop in revenue, according to its preliminary earnings estimate released on 31 July 2026.
During the reporting period, revenue is projected at RMB 0.04–0.05 million, down about 99.50%–99.63% from RMB 10.90 million a year earlier. Management attributed the decline to the absence of one-off intellectual-property licensing income booked in the first half of 2025; comparable transactions underway in 2026 had not yet met revenue-recognition criteria.
Other income and gains are slated to come in at RMB 9.54–10.55 million, representing a year-on-year decrease of roughly 12.86%–21.16%.
Despite minimal top-line contribution, Recbio forecasts a significant improvement in profitability metrics:
• Loss before tax: RMB 201.02–222.18 million, versus RMB 339.57 million in 1H25, reflecting a 34.57%–40.80% reduction. • Net loss: RMB 201.23–222.41 million, narrowing 34.71%–40.93% from RMB 340.65 million. • Basic and diluted loss per share: RMB 0.33–0.36, an improvement of 49.14%–53.98% from RMB 0.71 previously.
Management cited lower R&D expenses as the primary driver of the narrowed loss. The company has completed the major investment phase for clinical trials of its core vaccine candidates and has begun transitioning resources toward registration reviews and commercialisation preparations.
Recbio emphasised that the figures are unaudited estimates; definitive results will be disclosed in the forthcoming 2026 interim report. The company noted no major uncertainties affecting the accuracy of the preliminary data but advised investors to exercise caution when dealing in its securities.
Comments